Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Common Equity (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Common Equity for 8 consecutive years, with $92.2 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 63.58% to $92.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $92.2 million through Dec 2025, up 63.58% year-over-year, with the annual reading at $92.2 million for FY2025, 63.58% up from the prior year.
  • Common Equity for Q4 2025 was $92.2 million at Precision Biosciences, up from $16.6 million in the prior quarter.
  • The five-year high for Common Equity was $103.0 million in Q2 2022, with the low at $16.6 million in Q3 2025.
  • Average Common Equity over 5 years is $60.9 million, with a median of $59.6 million recorded in 2021.
  • The sharpest move saw Common Equity surged 198.99% in 2024, then plummeted 74.36% in 2025.
  • Over 5 years, Common Equity stood at $91.2 million in 2021, then crashed by 33.71% to $60.4 million in 2022, then tumbled by 68.79% to $18.9 million in 2023, then soared by 198.99% to $56.4 million in 2024, then surged by 63.58% to $92.2 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $92.2 million, $16.6 million, and $34.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.